Autoleucerous ciltacabtagen, also known as Carvykti, is a new treatment for multiple myeloma. The treatment involves genetically modifying the body's immune cells.
It reduces the risk of progression of the rare blood cancer by 74%, a study found. It is a promising cure for the disease, which affects 7 out of 100,000 people in the U.S. each year. The number of serious to life-threatening adverse events was slightly higher in the CarvyKti group.